The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Politics

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by admin October 3, 2025
October 3, 2025
Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Federal judge to sentence Justice Brett Kavanaugh’s attempted assassin
next post
Reagan-appointed judge, once rebuked by Supreme Court, continues to lambaste Trump

Related Posts

Mike Johnson mounts 20-state blitz to keep House...

August 6, 2024

Harris was ‘reluctant’ to choose Shapiro because of...

August 7, 2024

Trump orders Attorney General to investigate Biden’s autopen...

June 5, 2025

Trump calls for Jordan, Egypt to accept more...

January 26, 2025

Key GOP senator defects on crucial vote, imperiling...

June 29, 2025

Trump picks former congressman Pete Hoekstra to be...

November 21, 2024

Trump meets everyday Americans at Chick-fil-A while Biden...

April 12, 2024

‘Most damning evidence’: Hunter Biden’s full pardon resurfaces...

December 6, 2024

Federal judge rules Trump appointee Alina Habba is...

August 22, 2025

Trump announces new ‘serious power’ fighter jets for...

April 30, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Ben & Jerry’s co-founder resigns, claiming parent company Unilever ‘silenced’ its campaigning

      October 10, 2025
    • The Real Drivers of This Market: AI, Semis & Robotics

      October 10, 2025
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

      October 10, 2025
    • Could Trump win the Nobel Peace Prize after Israel-Hamas deal?

      October 10, 2025
    • RFK Jr shocked over pregnant moms protesting Trump with Tylenol: ‘Pathological’

      October 10, 2025
    • Top insurance CEO in the hot seat after scathing ad campaign exposes China ties

      October 10, 2025

    Categories

    • Business (1,416)
    • Politics (4,700)
    • Stocks (1,699)
    • Uncategorized (45)
    • World News (1,409)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved